Product title
Vendor
$19.99 | $24.99
Product title
Vendor
$19.99 | $24.99
Product title
Vendor
$19.99 | $24.99
Product title
Vendor
$19.99 | $24.99
Supports Heart Health in Dogs With MMVD
Product Description
VETMEDIN®-CA1 Chewable Tablets are a veterinary-prescribed heart medication designed to delay the onset of congestive heart failure in dogs with Stage B2 preclinical myxomatous mitral valve disease. Formulated with pimobendan, it supports heart muscle function and blood flow through a dual action mechanism. The chewable, scored tablets allow accurate dosing and easier administration for long-term cardiac care.
Benefits
- Delays Heart Failure: Helps extend the preclinical phase of Stage B2 MMVD by significantly delaying progression to congestive heart failure.
- Dual Action Support: Improves cardiac contractility and promotes vasodilation by increasing calcium sensitivity and inhibiting phosphodiesterase III.
- Proven Clinical Use: Supported by multi-site clinical studies showing longer time to heart failure compared to placebo-treated dogs.
- Easy Administration: Palatable chewable tablets with score lines allow accurate dosing and improved compliance in dogs.
Ingredients
Active Ingredients
Pimobendan
How to Use
Recommended Dosage Chart
|
Dog Body Weight |
Total Daily Labeled Dose |
Dosing Frequency |
|
Per lb body weight |
0.23 mg per lb |
Divided into two doses, approximately 12 hours apart |
Dosage & Administration Instructions
- Prescription Only: This product is labeled for use only by or on the order of a licensed veterinarian.
- Labeled Daily Dose: The total daily dose is labeled at 0.23 mg per lb body weight.
- Divided Dosing: The labeled daily amount is divided into two portions given approximately twelve hours apart.
- Scored Tablets: Chewable tablets are half-scored to allow dosing to the nearest half-tablet increment.
- Veterinary Oversight: Use is labeled only following veterinary diagnosis of Stage B2 preclinical MMVD.
Disclaimer: This dosage information is provided by the manufacturer. Always consult your veterinarian before administering or adjusting any supplement for your pet.
Additional Information
Precautions
- Restricted Conditions: Not labeled for dogs with hypertrophic cardiomyopathy, aortic stenosis, or inappropriate cardiac output conditions.
- Disease Stage Use: Labeled only for dogs with Stage B2 preclinical MMVD and confirmed cardiomegaly.
- Diagnostic Confirmation: Diagnosis should be supported by physical examination, radiography, and echocardiography findings.
- Limited Safety Data: Safety has not been established for dogs with non-MMVD heart disease or metabolic disorders.
Possible Side Effects
- Respiratory Signs: Cough and increased breathing rate may occur and are commonly associated with MMVD progression.
- Digestive Upset: Vomiting and diarrhea have been reported and were generally infrequent and self-limiting.
- Neurologic Events: Collapse, syncope, or seizures have been reported in some treated dogs.
- Cardiac Changes: Arrhythmias and lethargy may be observed and are often linked to disease progression.
Storage Information
- Room Temperature: Store at controlled room temperature between 20°C and 25°C.
- Temperature Excursions: Short-term storage between 15°C and 30°C is permitted.
- Secure Storage: Keep tablets in a secure location away from pets to prevent accidental ingestion.
Shipping & Return
We offer ground, express, priority, and international delivery; see our shipping policy for details.
For return instructions or product concerns, please refer to our detailed refund policy.
Prescription items are NON-RETURNABLE and NON-REFUNDABLE.
Frequently Asked Questions
Q1: What is VETMEDIN®-CA1 used for in dogs?
Ans: VETMEDIN®-CA1 is labeled to delay the onset of congestive heart failure in dogs diagnosed with Stage B2 preclinical myxomatous mitral valve disease. It is intended for dogs showing cardiomegaly and a moderate or loud mitral heart murmur, but no clinical heart failure signs.
Q2: How does pimobendan work in VETMEDIN®-CA1?
Ans: Pimobendan works through a dual mechanism by increasing calcium sensitivity in heart muscle fibers and inhibiting phosphodiesterase III. This combination supports stronger heart contractions and improved blood vessel relaxation, helping maintain effective cardiac function in dogs with preclinical MMVD.
Q3: Is VETMEDIN®-CA1 a prescription medication?
Ans: VETMEDIN®-CA1 is a prescription-only veterinary medication. Federal law restricts its use to dogs under the supervision or order of a licensed veterinarian. It should only be used following proper diagnosis and veterinary evaluation of Stage B2 preclinical MMVD.
Q4: Are there known side effects associated with VETMEDIN®-CA1?
Ans: Reported side effects in dogs receiving VETMEDIN®-CA1 include cough, lethargy, vomiting, diarrhea, tachypnea, and arrhythmias. Many reported effects are consistent with disease progression rather than direct drug-related toxicity when used at labeled doses.
Q5: Can VETMEDIN®-CA1 be used for all stages of heart disease?
Ans: VETMEDIN®-CA1 is not labeled for use in dogs with Stage A or Stage B1 MMVD or in conditions such as hypertrophic cardiomyopathy or aortic stenosis. Its approved use is limited to dogs with confirmed Stage B2 preclinical MMVD.
